Archive · 18 Jun 2025
India to Get Cheaper Weight-Loss Drugs, Lowering Global Costs
Drugs like Ozempic and Wegovy help people lose weight and control diabetes.
These drugs cost a lot.
But now, Indian companies are working to make cheaper versions when the original drug's patent expires.
This means more people in India and other countries might be able to afford them.
The makers of the original drug are also preparing to bring their own version to India sooner.
This could change who can get these medicines and how much they cost.
Indian pharmaceutical companies plan to launch cheaper versions of semaglutide, a weight-loss drug.
Novo Nordisk's patent for semaglutide expires in 2026, opening the market for generics.
Major Indian companies like Dr. Reddy's and Biocon are developing their own versions.
Indian manufacturers aim for a monthly cost as low as 500 rupees (under $6), a significant price reduction.
Novo Nordisk is accelerating the launch of Wegovy in India to compete with generics and Mounjaro.
- Who
- Indian pharmaceutical companies like Dr. Reddy's, Novo Nordisk, and patients.
- What
- Indian companies are preparing to launch low-cost versions of the weight-loss drug semaglutide.
- When
- Generics expected to be available by 2026, with accelerated launches possible.
- Where
- India and potentially other countries.
- Why
- To offer more affordable access to weight-loss and diabetes treatments.
Novo Nordisk
Indian Pharma Companies
Patent Protection
Novo Nordisk
Defends their patent rights against infringement.
Indian Pharma Companies
N/A
- Drugs Mentioned
- Semaglutide (Ozempic, Wegovy, Rybelsus), Tirzepatide (Mounjaro)
- Patent Expiration
- 2026 for semaglutide
- Companies Involved
- Dr. Reddy's, Sun Pharma, Cipla, Lupin, Biocon, Zydus Lifesciences, Novo Nordisk, Eli Lilly
- Potential Cost (India)
- Around 500 rupees/month (under $6)
- Global Market Forecast
- Over $100 billion by 2030
